SmarTrend analyzes over 5,000 stocks simultaneously on an intraday basis using its pattern recognition technology to give you real-time alerts for stocks on the move -- so you can maximize your trading results. Let our system increase your market awareness.
News Watch
- 9/30/2009 10:50:46 AM
By Chip Brian, SmarTrend Analytics Team
9/30/2009 - Discovery Labs (NASDAQ:DSCO) said Wednesday that following talks with the Food and Drug Administration, it may be able to continue with its Surfaxin program. The FDA had delayed the respiratory drug for infants as it requested more information about the drug's shelf life. The company is confident that after the discussion it will be able to move forward, aiming for protocol FDA submission in the fourth quarter. Shares of DSCO moved 32.4% higher during early Wednesday trading.
Contact Chip Brian
SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com. Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at www.TradeTheTrend.com/signup.html
|
